NOD-like receptor protein 3 and high mobility group box-1 are associated with prognosis of patients with congenital heart disease
| Autor: | Luyan Yu, Shanshan Shi, Yunxiang Qiu, Xiujing Wu, Zhijie Zheng, Jiajie Fan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Heart Defects Congenital Male Medicine (General) medicine.medical_specialty Prospective Clinical Research Report Heart disease chemical and pharmacologic phenomena NLR Proteins Nod 030204 cardiovascular system & hematology HMGB1 Biochemistry 03 medical and health sciences R5-920 0302 clinical medicine children Internal medicine NLR Family Pyrin Domain-Containing 3 Protein medicine Humans HMGB1 Protein Receptor Congenital heart disease biology integumentary system business.industry Biochemistry (medical) Infant Newborn NOD-like receptor Cell Biology General Medicine Plasma levels medicine.disease Prognosis high mobility group box-1 030104 developmental biology Endocrinology High-mobility group biology.protein NOD-like receptor protein 3 Female business Biomarkers |
| Zdroj: | The Journal of International Medical Research Journal of International Medical Research, Vol 48 (2020) |
| ISSN: | 1473-2300 0300-0605 |
| Popis: | Objective To investigate the association between plasma levels of nucleotide-binding oligomerization domain-like (NOD)-like receptor protein 3 (NLRP3) and high mobility group box-1 (HMGB1) and their prognostic significance in neonatal patients with congenital heart disease (CHD). Methods This study enrolled neonatal patients with CHD and collected their demographic and clinical data. Plasma concentrations of NLRP3 and HMGB1 were measured using enzyme-linked immunosorbent assays. Spearman’s analysis was used to determine the correlation between NLRP3 and HMGB1 levels. The association between NLRP3 and HMGB1 levels and 2-year survival and mortality were evaluated using Kaplan–Meier curve and logistic regression analyses. Results A total of 84 neonatal patients with CHD were included in the study. Plasma NLRP3 and HMGB1 levels were significantly higher in deceased patients compared with those that survived. There was a positive correlation between NLRP3 and HMGB1 levels in neonatal patients with CHD. Patients with elevated levels of NLRP3 and HMGB1 showed significantly lower 2-year survival and higher mortality rates compared with those with lower NLRP3 and HMGB1 levels. Conclusion Neonatal patients with CHD and a poor prognosis had higher NLRP3 and HMGB1 levels, which suggests that these might be potential biomarkers of CHD prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|